You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 23, 2025

Details for Patent: 10,266,523


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,266,523 protect, and when does it expire?

Patent 10,266,523 protects ODOMZO and is included in one NDA.

This patent has three patent family members in three countries.

Summary for Patent: 10,266,523
Title:Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4'-(trifluo- romethoxy) [1,1'-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Abstract: The present disclosure relates to novel crystalline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluo- romethoxy) [1,1'-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug. ##STR00001##
Inventor(s): Chen; Minhua (Jiangsu, CN), Zhang; Yanfeng (Suzhou, CN), Lu; Fei (Suzhou, CN), Zhang; Xiaoyu (Suzhou, CN)
Assignee: CRYSTAL PHARMATECH CO., LTD. (Suzhou, CN)
Application Number:15/579,881
Patent Claim Types:
see list of patent claims
Composition; Compound; Process;
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,266,523

Introduction

United States Patent 10,266,523, titled "Crystalline Forms of Monophosphate," is a patent that delves into the preparation and characteristics of specific crystalline forms of a monophosphate compound. This analysis will explore the patent's scope, claims, and the broader patent landscape in which it resides.

Patent Overview

The patent, filed under the application number US15/579,881, pertains to medicinal preparations containing organic active ingredients, specifically focusing on crystalline forms of a monophosphate compound. The patent is categorized under various international patent classifications, including A61K31/00, A61K31/33, and A61K31/395, indicating its relevance to medicinal preparations and heterocyclic compounds[4].

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims are crucial as they outline what the patent holder can legally enforce as their exclusive right.

  • Claim 1: This claim describes the crystalline Form A of the monophosphate compound, characterized by specific X-ray powder diffraction peaks. For example, the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 17.5° ± 0.2°, 5.1° ± 0.2°, and 13.0° ± 0.2°[4].

  • Claim 2: This claim details another crystalline form, Form B, with different X-ray powder diffraction peaks, such as 17.2° ± 0.2°, 15.4° ± 0.2°, and 25.0° ± 0.2°[4].

Dependent Claims

Dependent claims further specify the invention by adding additional limitations to the independent claims. These claims often describe specific processes, compositions, or uses of the crystalline forms.

  • Dependent Claims: These include claims related to the process of preparation of the crystalline forms, coating layers for the crystalline forms (e.g., shellac isolation coating, sugar coating), and the use of excipients such as water, oils, and glycols[4].

Scope of the Patent

The scope of the patent is defined by the claims and the detailed description provided in the patent document.

Crystalline Forms

The patent focuses on two primary crystalline forms, Form A and Form B, each with distinct X-ray powder diffraction patterns. These forms are significant due to their stability and low hygroscopicity, making them suitable for storage and use in pharmaceutical applications[4].

Stability and Hygroscopicity

The crystalline forms described in the patent have good stability and low hygroscopicity, which are critical properties for pharmaceutical compounds. This ensures that the compounds do not undergo unwanted crystal transformations, which could affect their efficacy and shelf life[4].

Coating and Excipients

The patent also covers various coating layers and excipients that can be used with the crystalline forms. This includes polymer coatings, anti-sticking agents, and other additives that enhance the formulation's stability and usability[4].

Broader Patent Landscape

Trends in Pharmaceutical Patents

The pharmaceutical sector has seen significant patent activity in recent years, with a focus on novel crystalline forms and formulations. This trend is driven by the need for stable and effective pharmaceutical compounds. The USPTO's Patent Claims Research Dataset provides insights into such trends, showing an increase in patents related to medicinal preparations and their formulations[5].

Patent Scope and Claims Analysis

Research on patent scope and claims, such as the work by Marco, Alan C., and Sarnoff, Joshua D., highlights the importance of measuring patent scope through metrics like independent claim length and independent claim count. These metrics can indicate the breadth and clarity of the patent claims, which are crucial for determining the patent's validity and enforceability[3][5].

Economic and Legal Implications

Market Impact

Patents like US 10,266,523 can have a significant impact on the pharmaceutical market. By securing exclusive rights to specific crystalline forms, the patent holder can control the production and distribution of these compounds, potentially influencing market prices and availability.

Litigation and Licensing

The patent's scope and claims can also affect litigation and licensing strategies. Clear and narrow claims, as validated by research, are more likely to withstand legal challenges and facilitate smoother licensing agreements[3].

Key Takeaways

  • Crystalline Forms: The patent focuses on two distinct crystalline forms of a monophosphate compound, each with specific X-ray powder diffraction patterns.
  • Stability and Hygroscopicity: The crystalline forms are characterized by good stability and low hygroscopicity, making them suitable for pharmaceutical use.
  • Coating and Excipients: The patent covers various coating layers and excipients that enhance the formulation's stability and usability.
  • Broader Trends: The patent is part of a broader trend in pharmaceutical patents, emphasizing novel crystalline forms and formulations.
  • Economic and Legal Implications: The patent's scope and claims have significant implications for market control, litigation, and licensing.

FAQs

  1. What is the main subject of United States Patent 10,266,523?

    • The main subject is the crystalline forms of a monophosphate compound, specifically their preparation and characteristics.
  2. What are the key characteristics of the crystalline forms described in the patent?

    • The crystalline forms are characterized by specific X-ray powder diffraction peaks and have good stability and low hygroscopicity.
  3. How do coating layers and excipients relate to the patent?

    • The patent covers various coating layers and excipients that can be used with the crystalline forms to enhance their stability and usability.
  4. What is the significance of the patent in the broader pharmaceutical sector?

    • The patent is part of a trend focusing on novel crystalline forms and formulations, which is crucial for developing stable and effective pharmaceutical compounds.
  5. How can the scope and claims of the patent impact litigation and licensing?

    • Clear and narrow claims can help the patent withstand legal challenges and facilitate smoother licensing agreements.

Sources

  1. Google Patents - US10266523B2

    • This source provides the detailed patent document for US 10,266,523, including claims and descriptions.
  2. Patent Claims Research Dataset - USPTO

    • This dataset offers insights into trends and metrics related to patent claims and scope.
  3. Patent Claims and Patent Scope - SSRN

    • This paper discusses metrics for measuring patent scope and their implications.
  4. Recent Trends in Article of Manufacture of Design Claims - Quarles

    • Although not directly related, this article provides context on broader patent trends and the importance of specific claim types.
  5. Data Download Tables - PatentsView

    • This resource offers access to patent data sets, which can be used to analyze broader patent trends and landscapes.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,266,523

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sun Pharm ODOMZO sonidegib phosphate CAPSULE;ORAL 205266-001 Jul 24, 2015 RX Yes Yes ⤷  Try for Free ⤷  Try for Free Y Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,266,523

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
China2015 1 0144499Mar 30, 2015
PCT Information
PCT FiledMarch 30, 2016PCT Application Number:PCT/CN2016/077886
PCT Publication Date:October 06, 2016PCT Publication Number: WO2016/155630

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.